-
Bioatla Inc NASDAQ:BCAB BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow it to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.
Location: | Website: www.bioatla.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
33.29M
Cash
61.66M
Avg Qtr Burn
-26.82M
Short % of Float
11.92%
Insider Ownership
10.76%
Institutional Own.
50.64%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ozuriftamab vedotin (BA3021) (ROR2-ADC) Details Cancer, Melanoma | Phase 2 Data readout | |
mecbotamab vedotin (BA3011) (anti-AXL ADC) Details Solid tumor/s, Soft tissue sarcoma, Bone sarcoma, Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
Evalstotug (BA3071) + Pembrolizumab Details Solid tumor/s, Cancer, Melanoma, Non-small cell lung carcinoma | Phase 2 Data readout | |
Ozuriftamab vedotin (BA3021) (ROR2-ADC) Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma | Phase 2 Update | |
Evalstotug (BA3071) (CAB anti-CTLA-4 antibody) w/ nivolumab Details Solid tumor/s, Cancer | Phase 2 Update | |
CAB-EpCAM x CAB-CD3 TCE (BA3182) Details Cancer, Carcinoma | Phase 1 Data readout |